“With the appointment of Dilawar Syed as CEO, we have found not only an excellent and highly experienced leader, but also someone who knows how to build and grow enterprise products,” said Matt Downs, chairman of the Lumiata board of directors. “Syed has already hit the ground running since joining Lumiata. In just a matter of weeks, he has led the company in securing this new round of funding and is firmly at the helm as Lumiata accelerates development of a new suite of predictive analytics products to support payers and risk-bearing entities.”
Lumiata’s models predict disease risk and certain chronic condition onset for over 20 million patient lives.